ratio

Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting

GENEVA, July 11, 2007 /PRNewswire/ -- InspirationBiopharmaceuticals today announced the presentation of preclinicaldata supporting the development of new, proprietary forms ofrecombinant Factor IX to treat patients with Hemophilia B. The datawere highlighted in an oral presentation and a poster session atthe XXIst Congress of the International Society on Thrombosis andHaemostasis (ISTH)...

Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- AlfacellCorporation today announced that Lawrence A. Kenyon, executive vicepresident, chief financial officer and corporate secretary, willpresent an overview of the company's product development programsat 8 a.m. EDT on Thursday, July 12, 2007, at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference in New York. The aud...

Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine

- Article Discussing Pharmacokinetics and Dose Proportionality ofCompany's Once-Daily Tramadol to be Published in BiopharmaceuticsJournal - LAVAL, QC, June 29, 2007 /PRNewswire-FirstCall/ - Labopharm Inc.today announced that it will present a poster discussing the dosetitration of its once-daily formulation of tramadol at the 3rdInternational Forum on Pain Medicine to be held June 28 to J...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, announced todaythat its proprietary Duocalin(R) technology has successfullydemonstrated dual targeting potential. Commenting on this development, Dr Andreas Hohlbaum, Director ofScience and Preclinical D...

Diabetes drug supported by Mexican Diabetes Federation

VANCOUVER, June 21, 2007 /PRNewswire-FirstCall/ - BiotechHoldings reports that the Mexican Diabetes Federation has givenBiotech's "Sucanon" diabetes drug its support in an overview ofdiabetic drugs published in the May-June 2007 issue of DiabetesHoy, the Diabetic Federation's scientific and medical magazine fordoctors and other health professionals. The overview of diabetic drugs,...

Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron

BILLERICA, Massachusetts --- June20, 2007 --- Millipore Corporation today announced the release ofnew data concerning its ReNcell neural stem cell lines. Theresearch was conducted by the Department of Physiology atUniversity College London and ReNeuron Group plc, whose ReNcelldistribution agreement with Millipore was announced in 2006. The data will be presen...

First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy

ROANOKE, Va.--(BUSINESS WIRE)--Jun 20, 2007 - Researchers from LunaInnovations Incorporated (NASDAQ: LUNA) and Virginia CommonwealthUniversity (VCU) are the first to show that carbon nanospheres,sometimes referred to as "buckyballs," are able to block allergicresponse in human cell culture experiments and mice. These findingsare described in a paper entitled "Fullerene Nanomaterials Inhibit...

Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study

RALEIGH, N.C.--(BUSINESS WIRE)--Jun 18, 2007 - SalixPharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successfulcompletion and outcome of its Phase III registration trial toevaluate the safety and efficacy of a new 1100 mg tabletformulation of balsalazide disodium (balsalazide tablets).Balsalazide disodium is the active ingredient in COLAZAL(R)Capsules 750 mg, an anti-inflammatory dru...

Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration

PARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory News-Ipsen(Paris:IPN) announced today that the preliminary data from theongoing phase III study for its investigational 4-month formulationof triptorelin do not support the expected sustainable blood levelsof triptorelin for a duration of 4 months in all patients.Therefore, Ipsen has decided not to perform the secondadministration as planned...

Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, made a posterpresentation at the 2007 Annual Meeting of the Federation ofClinical Immunology Societies (FOCIS) in San Diego June 7-11 at theSheraton San Diego Hotel & Marina. The poster, entitled"Identifying New Immuno...

Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today that thecompany's partner, Vical Incorporated, presented positive interimsafety and tolerability data on 18 subjects from an ongoing Phase Iclinical trial...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its electroporation-mediated DNAdelivery te...

Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing

Phase I results for CPX-1 presented at ASCO confirm safety findingsand demonstrate clinical benefit in more than 70% of patients withcolorectal and other types of cancer. PRINCETON, N.J., June 04, 2007 /PRNewswire/ -- CelatorPharmaceuticals announced positive safety and efficacy results fromits Phase I study of CPX-1 (Irinotecan HCI:Floxuridine), LiposomeInjection in patients with heavily...

Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- BostonScientific Corporation today welcomed the publication of an articlein the Journal of of Cardiology (JACC) reviewing the TAXUS ATLASclinical trial, which evaluates the Company's second-generationTAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. Thearticle in the April 24 edition of JACC concluded that the shorterprocedure...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

Clinical Benefit Shown in 35% of HER2-Positive Metastatic BreastCancer Patients HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that alvespimycin, its second-generation Hsp90inhibitor, demonstrated promising antitumor activity andtolerability in combination with trastuzumab (Herceptin(R)) inpatient...

Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...

Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor IanMeredith, M.D., Monash Medical Centre, Melbourne, Australia, onTuesday presented positive nine-month results from the MedtronicRESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain,with data showing a low number of adverse cardiac events and noprotocol-defined stent thrombosis. The next-generation Medtronic(NYSE:MDT...

NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis

ANN ARBOR, Mich., May 22, 2007 /PRNewswire/ -- NanoBioCorporation, a biopharmaceutical company developing novel productsfor the treatment and prevention of serious infections, todayannounced positive safety data from its Phase 1 clinical study ofNB-002, the company's drug candidate currently in a Phase 2clinical trial for the topical treatment of onychomycosis. The Phase 1 clinical...

Alterations in Intestinal Serotonin in Irritable Bowel Syndrome and Dyspepsia

ROCHESTER, MN, May 21, 2007-- Serotonin is aneurotransmitter that helps regulate intestinal functions. MayoClinic researchers set out to determine the role of serotonin inpatients with IBS and dyspepsia. The study involved 48 females --including individuals with IBS, individuals with dyspepsia,individuals with both IBS and dyspepsia, and healthy volunteers.Biopsies were obtained from the...

Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease

Announces Plans for Advancing AT-1001 into Later Stage ClinicalTrials BALTIMORE, May 07, 2007 /PRNewswire/ -- Alba TherapeuticsCorporation today announced preliminary results from its Phase IIaclinical trial for AT-1001 in subjects with Celiac Disease (CD), anautoimmune disease affecting over 3 million people in the UnitedStates. Alba's study, the first Phase IIa trial in CD and the first...

OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology

WALTHAM, Mass.--(BUSINESS WIRE)--May 7, 2007 - OXiGENE, Inc.(NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology companydeveloping novel therapeutics to treat cancer and eye diseases,announced today that the results of its Phase II combretastatin A4phosphate (CA4P) clinical trial in myopic macular degeneration(MMD) was presented at the 47th Annual Meeting of the Associationof Research...

Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting

Statistically Significant Improvements in Function in Spinal CordInjury Model With ZFP TF Treatment RICHMOND, Calif., May 03, 2007 /PRNewswire-FirstCall/ -- SangamoBioSciences, Inc. announced today the presentation of preclinicaldata from its ZFP Therapeutic(TM) program in nerve regeneration atthe Fourteenth Annual Conference of the American Society for NeuralTherapy and Repair. The data...

EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting

Supports Local Mechanism of Action of NP-1 in Neuropathic Pain TARRYTOWN, N.Y., May 03, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation announced today that it will present new data forEpiCept(TM) NP-1 on Thursday, May 3, 2007 at the 26th AnnualScientific Meeting of the American Pain Society in Washington D.C.EpiCept NP-1 is a patented topical cream formulation of twoFDA-approved drugs,...

Labtec’s Next Generation Pain Patch Successful in Clinical Studies

LANGENFELD, Germany, April 25, 2007-Labtec GmbH (Langenfeld,Germany), a specialty pharmaceutics company announces positiveresults from a multiple dose clinical study for their proprietarySufentanil transdermal patch. “Today, we are pleased to announce the successfulcompletion of the second clinical trial for our SufentanilTDS®. Our goal for this program was to complete th...

Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune

CARLSBAD, Calif., April 23, 2007 /PRNewswire-FirstCall/Micromet, Inc. today announced the achievement of a milestone inits research collaboration with MedImmune, Inc. for the developmentof new BiTE(R) molecules targeting carcinoembryonal antigen (CEA),a validated tumor- associated antigen frequently expressed onvarious human carcinomas. Preclinical data recently presented atthe 2007 Annu...

Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets

Data Presented at Society for Biomolecular Sciences Conference THE WOODLANDS, Texas, April 18, 2007 /PRNewswire-FirstCall/ --Lexicon Genetics Incorporated announced that data was presentedtoday highlighting potential therapeutic targets related to itscollaboration with Genentech, Inc. at the Society for BiomolecularSciences 13th Annual Conference & Exhibition in Montreal,Canada. These...

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, discussed results from two pre-clinical studies thatprovide evidence for chemotherapy induced angiogenesis andrationale for combining nab-paclitaxel (ABRAXANE(R) for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension) (albumin-bou...

Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR

HAYWARD, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated today presented preclinical data onKOS-1803, a next-generation epothilone, showing a high level ofantitumor activity and a favorable pharmacokinetic and safetyprofile in a broad range of in vitro tests and in vivo cancermodels. KOS-1803 has been chemically engineered to have a favorabletissue distribu...

Afid Therapeutics Obtains Positive Evaluation of its Triple Mode Viral Sequestration Agents

LANSING, Mich., March 27, 2007 /PRNewswire/ -- AfidTherapeutics, Inc. announced that it received positive results onthe ability of its new triple mode viral sequestration agents toblock viral infections of mammalian cells. The audited results wereobtained from a specialized, independent third party testingorganization. The new viral sequestrating agents are designed tobind and inactivate...

Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration

TARRYTOWN, N.Y. & LEVERKUSEN, Germany--(BUSINESS WIRE)--Mar 27,2007 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and BayerHealthCare AG (NYSE: BAY) today announced positive preliminary datafrom a pre-planned interim analysis of a Phase 2 randomized studyof their VEGF Trap-Eye in patients with the neovascular form ofage-related macular degeneration (wet AMD). The VEGF Trap-Eye metits...

CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant

- Tyrima Demonstrates Good Safety Profile and ExcellentPharmacokinetic Properties - RESEARCH TRIANGLE PARK, N.C., March 13, 2007 /PRNewswire/ --CeNeRx BioPharma, Inc., a clinical stage company developing andcommercializing innovative treatments for diseases of the centralnervous system, today announced top-line results from a Phase Iclinical trial of Tyrima(TM), its lead candidate for the...

Vaxiion Researchers Discover Novel Vaccine Delivery System in Collaboration with San Diego State University

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Vaxiion Therapeutics,Inc. today announced that its researchers, in collaboration withSan Diego State University, have discovered a 'minicell' vaccinedelivery system that has potential to protect against severaldisease-causing infections. These findings were published in an advance online edition ofthe journal, Vaccine, and the paper was published...

BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality

JERUSALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd.(TASE:BLRX), Israel's leading drug development company, reportedtoday pre-clinical data from trials of BL-1040 demonstrating thatBL-1040 is effective in preventing deterioration of the myocardiumafter a myocardial infarction (MI), thereby reducing left ventricledilatation and eventual heart failure in a pig model. ProfessorJonathan Leo...